Kutane bivirkninger ved behandling med immuncheckpointinhibitorer

Jeanette Kaae; Aska Drljevic-Nielsen; Jesper Palshof; Inge Marie Svane; Christian Vestergaard; Berit Christina Carlsen

doi:10.61409/V03240216

Kutane bivirkninger ved behandling med immuncheckpointinhibitorer

Jeanette Kaae^*, Aska Drljevic-Nielsen, Jesper Palshof, Inge Marie Svane, Christian Vestergaard, Berit Christina Carlsen

^*Corresponding author af dette arbejde

Dermatologisk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.

Bidragets oversatte titel	Cutaneous side effects of treatment with immune checkpoint inhibitors
Originalsprog	Dansk
Artikelnummer	V03240216
Antal sider	9
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	29
DOI	https://doi.org/10.61409/V03240216
Status	Udgivet - 15 jul. 2024

Emneord

Drug Eruptions/etiology
Humans
Immune Checkpoint Inhibitors/adverse effects
Neoplasms/drug therapy

Adgang til dokumentet

10.61409/V03240216Licens: CC BY-NC-ND

Citationsformater

@article{144cc252777d4678b6fed78e8db57ac7,

title = "Kutane bivirkninger ved behandling med immuncheckpointinhibitorer",

abstract = "Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.",

keywords = "Drug Eruptions/etiology, Humans, Immune Checkpoint Inhibitors/adverse effects, Neoplasms/drug therapy",

author = "Jeanette Kaae and Aska Drljevic-Nielsen and Jesper Palshof and Svane, \{Inge Marie\} and Christian Vestergaard and Carlsen, \{Berit Christina\}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = jul,

day = "15",

doi = "10.61409/V03240216",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "29",

}

TY - JOUR

T1 - Kutane bivirkninger ved behandling med immuncheckpointinhibitorer

AU - Kaae, Jeanette

AU - Drljevic-Nielsen, Aska

AU - Palshof, Jesper

AU - Svane, Inge Marie

AU - Vestergaard, Christian

AU - Carlsen, Berit Christina

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/7/15

Y1 - 2024/7/15

N2 - Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.

AB - Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.

KW - Drug Eruptions/etiology

KW - Humans

KW - Immune Checkpoint Inhibitors/adverse effects

KW - Neoplasms/drug therapy

U2 - 10.61409/V03240216

DO - 10.61409/V03240216

M3 - Review

C2 - 39115212

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 29

M1 - V03240216

ER -

Kutane bivirkninger ved behandling med immuncheckpointinhibitorer

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater